CA2269256A1 - Substituted tricyclics - Google Patents

Substituted tricyclics Download PDF

Info

Publication number
CA2269256A1
CA2269256A1 CA002269256A CA2269256A CA2269256A1 CA 2269256 A1 CA2269256 A1 CA 2269256A1 CA 002269256 A CA002269256 A CA 002269256A CA 2269256 A CA2269256 A CA 2269256A CA 2269256 A1 CA2269256 A1 CA 2269256A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
nitrogen
group
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002269256A
Other languages
English (en)
French (fr)
Inventor
Daniel Jon Sall
Edward David Mihelich
John Michael Morin Jr.
Edward C.R. Smith
Douglas Wade Beight
Jason Scott Sawyer
Tulio Suarez
Nicholas James Bach
Thomas Michael Wilson
Jolie Anne Bastian
Qiuping Wang
Michael Dean Kinnick
Michael John Martinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2269256A1 publication Critical patent/CA2269256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002269256A 1998-04-17 1999-04-16 Substituted tricyclics Abandoned CA2269256A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17
US09/062,165 1998-04-17

Publications (1)

Publication Number Publication Date
CA2269256A1 true CA2269256A1 (en) 1999-10-17

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269256A Abandoned CA2269256A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Country Status (27)

Country Link
EP (2) EP1156050B1 (enExample)
JP (1) JP4435325B2 (enExample)
KR (1) KR19990083234A (enExample)
CN (1) CN1235968A (enExample)
AR (1) AR018185A1 (enExample)
AT (2) ATE254128T1 (enExample)
AU (1) AU757454B2 (enExample)
BR (1) BR9901275A (enExample)
CA (1) CA2269256A1 (enExample)
CO (1) CO5080728A1 (enExample)
CZ (1) CZ137199A3 (enExample)
DE (2) DE69912670T2 (enExample)
EA (1) EA003129B1 (enExample)
ES (2) ES2210979T3 (enExample)
HU (1) HUP9901219A1 (enExample)
ID (1) ID23219A (enExample)
IL (1) IL129484A0 (enExample)
NO (1) NO991823L (enExample)
NZ (1) NZ335252A (enExample)
PE (1) PE20000472A1 (enExample)
PL (1) PL332564A1 (enExample)
SG (1) SG106035A1 (enExample)
SV (1) SV1999000052A (enExample)
TR (1) TR199900842A2 (enExample)
TW (1) TW555760B (enExample)
YU (1) YU19099A (enExample)
ZA (1) ZA992773B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
AU2001244635A1 (en) * 2000-03-30 2001-10-15 Yamanouchi Pharmaceutical Co..Ltd. Hydrazide derivatives
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
AU2002239264A1 (en) * 2000-12-18 2002-07-01 Eli Lilly And Company Tetracyclic derivatives as spla2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
JP2005527466A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
MX2007005199A (es) 2004-11-01 2007-05-11 Wyeth Corp Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
BRPI0907122B8 (pt) 2008-01-11 2021-05-25 Albany Molecular Res Inc compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
JP5964945B2 (ja) * 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
SMT201700009T1 (it) 2012-03-16 2017-03-08 Vitae Pharmaceuticals Inc Modulatori del recettore x del fegato

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease

Also Published As

Publication number Publication date
TW555760B (en) 2003-10-01
HUP9901219A1 (hu) 2000-08-28
NO991823L (no) 1999-10-18
JPH11322745A (ja) 1999-11-24
AR018185A1 (es) 2001-10-31
KR19990083234A (ko) 1999-11-25
DE69914951D1 (de) 2004-03-25
CN1235968A (zh) 1999-11-24
DE69914951T2 (de) 2004-12-23
ATE259818T1 (de) 2004-03-15
ES2210979T3 (es) 2004-07-01
AU2381899A (en) 1999-10-28
EP1156050B1 (en) 2004-02-18
ID23219A (id) 2000-03-30
EP0950661B1 (en) 2003-11-12
ES2213668T3 (es) 2004-09-01
JP4435325B2 (ja) 2010-03-17
CO5080728A1 (es) 2001-09-25
EA003129B1 (ru) 2003-02-27
YU19099A (sh) 2001-09-28
NZ335252A (en) 2000-11-24
PE20000472A1 (es) 2000-06-02
HU9901219D0 (en) 1999-06-28
TR199900842A2 (xx) 2000-09-21
ATE254128T1 (de) 2003-11-15
EA199900304A2 (ru) 1999-10-28
EA199900304A3 (ru) 2000-04-24
SG106035A1 (en) 2004-09-30
EP1156050A2 (en) 2001-11-21
DE69912670T2 (de) 2004-08-12
AU757454B2 (en) 2003-02-20
ZA992773B (en) 2002-07-16
IL129484A0 (en) 2000-02-29
SV1999000052A (es) 2000-03-14
CZ137199A3 (cs) 1999-11-17
DE69912670D1 (de) 2003-12-18
EP0950661A1 (en) 1999-10-20
EP1156050A3 (en) 2001-11-28
BR9901275A (pt) 2000-05-02
PL332564A1 (en) 1999-10-25
NO991823D0 (no) 1999-04-16

Similar Documents

Publication Publication Date Title
US6177440B1 (en) Substituted tricyclics
CA2269246C (en) Substituted tricyclics
KR100808742B1 (ko) 테트라하이드로피리도인돌 유도체
EP0839806B1 (en) Substituted tricyclics
AU757454B2 (en) Substituted tricyclics
US6974831B2 (en) sPLA2 inhibitors
CA2335448A1 (en) Bicyclic spla2 inhibitors
US6713645B1 (en) Substituted tricyclics
CA2338855A1 (en) Indole spla2 inhibitors
US6448284B1 (en) Substituted tricyclics
US20040087796A1 (en) Substituted carbazoles as inhibitors of spla2
HK1025091A (en) Substituted tricyclics useful in spla2 induced diseases
MXPA99003588A (en) Triciclic composites substitui
EP1349836B1 (en) Tetracyclic derivatives as spla2 inhibitors
US20040063967A1 (en) Novel spla2 inhibitors
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
MXPA99003587A (es) Compuestos triciclicos substituidos
HK1010546A (en) Substituted tricyclics
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued